Mostrar el registro sencillo del ítem

Effect of combined treatment of selective serotonin reuptake inhibitors plus immunomodulator on circulating cytokines levels in patients with major depressive disorder along 52 weeks of follow up 

dc.creatorPavon, Lenin
dc.creatorEugenia Hernandez, Maria
dc.creatorMayra Perez-Tapia, Sonia
dc.creatorMendieta, Danelia
dc.creatorBojalil, Rafael
dc.creatorEstrada-Garcia, Iris
dc.creatorEstrada-Parra, Sergio
dc.date.accessioned2017-06-29T03:46:35Z
dc.date.available2017-06-29T03:46:35Z
dc.date.issued2013es_ES
dc.identifier2663es_ES
dc.identifier.issn1740-2522es_ES
dc.identifier.uries_ES
dc.identifier.urihttp://repositorio.inprf.gob.mx/handle/123456789/4512
dc.language.isoenges_ES
dc.publisherHindawi Publishing Corporation, 410 Park Avenue, 15TH Floor, #287 PMB, New York, NY 10022 USA es_ES
dc.relation1-12p.es_ES
dc.relationversión del editores_ES
dc.rightsacceso cerradoes_ES
dc.subject.meshes_ES
dc.titleEffect of combined treatment of selective serotonin reuptake inhibitors plus immunomodulator on circulating cytokines levels in patients with major depressive disorder along 52 weeks of follow up es_ES
dc.title.alternativees_ES
dc.typeartículoes_ES
dc.contributor.affiliationInstituto Nacional de Psiquiatria Mexico, Laboratorio de Psicoinmunol, Mexico City, DF, Mexicoes_ES
dc.contributor.emailes_ES
dc.relation.jnabreviadoCLIN DEV IMMUNOLes_ES
dc.relation.journalClinical & developmental immunologyes_ES
dc.identifier.placeNew Yorkes_ES
dc.date.published2013es_ES
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñizes_ES
dc.identifier.eissn1740-2530es_ES
dc.identifier.doi10.1155/2013/267871es_ES
dc.description.monthSepes_ES
dc.description.abstractotrodiomaMajor depressive disorder (MDD) is a psychiatric illness that presents as a deficit of serotonergic eurotransmission in the central nervous system. MDD patients also experience alterations in cortisol and cytokines levels. Treatment with selective serotonin reuptake inhibitors (SSRIs) is the first-line antidepressant regimen for MDD. The aim of this study was to determine the effect of a combination of SSRIs and an immunomodulator—human dialyzable leukocyte extract (hDLE)—on cortisol and cytokines levels. Patients received SSRIs or SSRIs plus hDLE.The proinflammatory cytokines IL-1훽, IL-2, and IFN-훾; anti-inflammatory cytokines IL-13 and IL-10; and 24-h urine cortisol weremeasured at weeks (W) 0, 5, 20, 36, and 52 of treatment.Thereduction in cortisol levels in the SSRI-treated group was 30% until W52, in contrast, the combined treatment induced a 54% decrease at W36. The decline in cortisol in patients who were treated with SSRI plus hDLE correlated with reduction of anti-inflammatory cytokines and increases levels of proinflammatory cytokines at the study conclusion. These results suggest that the immune-stimulating activity of hDLE, in combination with SSRIs, restored the pro- and anti-inflammatory cytokine balance and cortisol levels in depressed patients versus those who were given SSRIs alone.es_ES
dc.subject.meshmes_ES
dc.subject.koes_ES


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem